A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

This study is testing whether a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) helps improve heart and lung function in people with COPD who also have lung overinflation — where air gets trapped in the lungs. **You may be eligible if...** - You are a current or former smoker with at least 10 pack-years of smoking history - You have a confirmed COPD diagnosis based on breathing tests - Your lung function falls within a moderate-to-severe range (FEV1 between 30–80% of predicted normal) - You have significant air trapping in your lungs (hyperinflation confirmed by breathing tests) - You experience breathlessness (mMRC score of 1 or higher) - Your blood eosinophil count is below 300 cells/mm³ - You are already on at least one inhaled COPD maintenance medication **You may NOT be eligible if...** - You have high eosinophil counts in your blood (over 300 cells/mm³) in the past 12 months - Your lung function is too severely impaired (FEV1 below 30%) or too mildly impaired - You do not have lung overinflation Talk to your doctor to see if this trial is right for you.